Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors

Summary

NOTE: This trial is currently enrolling into the extension arm. The purpose of this phase I trial is to evaluate the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial and confirmed at screening.

General Information

NCT#: NCT01376505
Study ID: OSU-09138
Trial Phase: Phase I

Trial Sponsor: Ohio State University
Therapies Used in This Trial: HER-2 vaccine

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search